Invention Grant
- Patent Title: MHC class I associated hepatitis B peptides
-
Application No.: US16168324Application Date: 2018-10-23
-
Publication No.: US11191828B2Publication Date: 2021-12-07
- Inventor: Ramila Philip
- Applicant: Emergex Vaccines Holding Ltd.
- Applicant Address: GB Abingdon
- Assignee: Emergex Vaccines Holding Ltd.
- Current Assignee: Emergex Vaccines Holding Ltd.
- Current Assignee Address: GB Abingdon
- Agent Joseph A. Aceto
- Main IPC: A61K39/29
- IPC: A61K39/29 ; A61K39/12 ; C07K14/005 ; C07K14/02 ; C12N7/00 ; G01N33/569 ; A61K39/00
Abstract:
The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease.
Public/Granted literature
- US20190038740A1 MHC Class I Associated Hepatitis B Peptides Public/Granted day:2019-02-07
Information query
